Tissue Engineering and Cell Transplantation: Technologies, Opportunities, and Evolving Markets
This article was originally published in Start Up
Executive Summary
In 2003, the combined US potential market for tissue-engineering products totaled approximately $58.1 billion. By 2013, the potential market is expected to increase at a compound rate of 4.8%, reaching $92.8 billion, with a number of segments growing at an even faster rate than the market overall.
You may also be interested in...
Scaffolds in Tissue Engineering
Stem-cell-related strategies may predominate these days in tissue engineering, but cell therapy companies know that providing the right microenvironment for nurturing tissue growth remains a difficult and essential challenge. Thus, start-ups remain committed to the developent of cellular matrices that provide the appropriate structure, environment, and bioactivity to encourage tissue growth. The four start-ups profiled in this issue represent a cross-section of strategies.
Clinical Update (03/2007)
Recent clinical developments in the medical device industry, including developments in Artificial Limbs, Tissue-Engineered Therapy for ACL Tears, using Genes to Identify Early Atherosclerosis, and Stem Cell News.
Why Millions from California Won't Get VCs to Fund Stem Cell Start-Ups--But What Will
Despite the millions of dollars from public initiatives, particularly in California, to fund stem-cell research, VCs will still probably stay away until Big Pharma and Big Biotech show more of their own R&D interest in the area.